IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Mirari Biosciences was founded in 2000 by CEO Mark Martin, who developed the MASC and Peplica technologies. Mirari Biosciences it working to cut down on the time its takes to test new drugs. The first of the company's two primary technologies is microwave-accelerated surface chemistry (MASC) which can speed up drug discovery tests, medical and veterinary diagnostics, and food and water testing by exposing test materials to low-heat microwaves. Its protein amplification technology (Peplica) replicates proteins which helps researchers locate and identify minute levels of proteins.

Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulin franchise, including modern insulins, human insulins, insulin-related sales, and oral antidiabetic drugs, as well as GLP-1 compounds in development for both the treatment of type 2 diabetes and as an anti-obesity agent. The Biopharmaceuticals segment provides products in the areas of haemostasis management, growth hormone therapy, hormone replacement therapy, inflammation therapy, and other therapy areas. The company sells its products principally in the United States, Japan, China, the Russian Federation, India, Turkey, and other European countries.

ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator is under review by the United States Food and Drug Administration (FDA), for chronic heart failure (HF). Gencaro is an oral tablet formulation, dosed twice daily. On January 27, 2009, Nuvelo, Inc. (Nuvelo) completed the merger with ARCA biopharma, Inc. (ABI). Pursuant to the Merger, Dawn Acquisition Sub, Inc. merged with and into ABI, with ABI continuing after the merger as the surviving company and a wholly owned subsidiary of Nuvelo. Pursuant to the Merger, ABI changed its name to ARCA biopharma Colorado, Inc. and Nuvelo changed its name to ARCA biopharma, Inc.

Vivalis SA was founded in 1999 and is headquartered in Saint-Herblain, France. Vivalis SA, a biopharmaceutical company, develops and sells cell-based solutions to the pharmaceutical industry for the manufacture of viral vaccines and therapeutic proteins. Its proprietary technologies include EB66 cell line platform, which is derived from duck embryonic stem cells that presents industrial and regulatory characteristics to replace the eggs in the production of vaccines and to produce antibodies with enhanced antibody dependent cell cytotoxicity activity; and the 3D-SCREEN molecular screening platform that is used to identify and develop molecules for the purpose of blocking the action of proteins involved in major viral pathologies. The company also develops drugs for the prevention and treatment of viral diseases, notably for the treatment of hepatitis C.

Founded in 1929, the not-for-profit organization is a leading researcher of human diseases, their causes, and their potential cures. Much of its research into mammalian genetics is focused on mice, which share a similar genetic makeup to humans. In addition to its own research in areas such as cancer, immunology, and metabolic disease, the organization maintains colonies of mice and supplies them under the brand name JAX to other laboratories around the globe. Additionally, The Jackson Laboratory offers educational programs -- including internships, workshops, and predoctoral programs -- for both current and future scientists.

Established in 1968 by French vet Pierre-Richard Dick, Virbac provides biological and pharmaceutical products for veterinary and animal health use and is one of the 10 biggest veterinary pharmaceutical companies in the world. Products include vaccines, flea treatments, wormers, and antibiotics for animals. With some 20 subsidiaries (including US-based Virbac Corporation), the company's products are sold in more than 100 countries. Virbac's companion animal segment (dogs, cats, horses) represents more than 60% of the company's sales, while its food-producing animal segment (cows, chickens, cattle) brings in about 37%. The founding Dick family owns about 50% of the company.

OSI Pharmaceuticals, Inc. company was founded in 1983 and is based in Melville, New York. OSI Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of molecular targeted therapies for the treatment of unmet medical needs in oncology, diabetes, and obesity. Its flagship product, Tarceva is a small molecule therapeutic designed to inhibit the receptor tyrosine kinase activity of the protein product of the HER1/EGFR gene. The company also offers Novantrone, a mitoxantrone for injection concentrate. OSI Pharmaceuticals products in Phase I clinical trials include OSI-906, an oral small molecule IGF-1R inhibitor for various cancers, including NSCLC, breast, pancreatic, prostate, colorectal, adrenocortical, and ovarian; PSN821, an oral small molecule drug with anti-diabetic and appetite suppressing effects developed for the treatment of type 2 diabetes; PSN602, a novel dual serotonin and noradrenaline reuptake inhibitor for the long-term treatment of obesity; and OSI-027, a small molecule TORC1/TORC2 inhibitor to supersede first generation mTOR inhibitors. The companys other development programs include OSI-296, a novel potent TKI developed to block compensatory signaling in epithelial tumor cells; OSI-930, a multi-targeted tyrosine kinase inhibitor that acts as a potent co-inhibitor of the receptor tyrosine kinases c-kit and the vascular endothelial growth factor receptor-2; OSI-632, an anti-angiogenesis agent; and CP-868,596, a PDGFR inhibitor. OSI Pharmaceuticals has collaboration agreements with Genentech, Inc.; Roche; and AVEO Pharmaceuticals, Inc.

Lyne Laboratories contract pharmaceutical manufacturer specializes in oral liquid formulations (with a bitter-taste blocker available), as well as powder-form, semi-solid, and tablet medicines. The company also offers analytical services, such as quality control and testing, and regulatory support services. Lyne Laboratories can whip up small test-size batches for clinical research as well as full production for commercial launches and provide regulatory support along the way. An explosion-proof production and storage facility has expanded its ability to produce flammable drugs.

Network Biosystems develops high throughput DNA sequencing systems with applications in the personalized medicine, forensics, drug discovery, and security arenas. The company blends nanotechnology and mircrofluidics to achieve its DNA analysis. Its sequencing systems were conceived at MIT's Whitehead Institute. The company is in the developmental stage and is pursuing a variety of commercial applications including manufacturing a rugged portable STR analysis and identification in the forensics field and on site screening of large numbers for use by homeland security.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.